New evidence on GLP-1 receptor agonists at ADA 2024

""

Further insights on glucagon-like peptide-1 (GLP-1) receptor agonists were presented at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida, 21-24 June.

Obesity affects 41.9% of adults and 19.7% of children and adolescents in the US, and 90% of people with diabetes also live with overweight or obesity.

“Over the past few years, we have seen the substantial impact of new research working to solve the dual health crisis we are facing, obesity and diabetes,” said Dr Robert Gabbay, Chief Scientific and Medical Officer for the ADA. “The studies we are seeing presented at this year’s annual meeting show great promise to fuel new solutions and treatment options for patients across the globe living with type 2 diabetes and obesity.”

Results of a Phase II study into HRS9531, a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, found it effectively reduced body weight, blood pressure, blood glucose, and triglycerides, with a favourable safety profile.

At the end of the 24-week intervention, participants in 1mg, 3mg, 4.5mg, and 6mg HRS9531 groups achieved weight reductions of 5.4%, 13.4%, 14.0%, and 16.8% respectively, as compared with 0.1% reduction in the placebo group. Moreover, the proportion of participants achieving ≥5% weight reduction was 52.0%, 88.2%, 92%, 91.8%, and 10.2%, respectively.

In another presented study, the Phase II MOMENTUM trial evaluated the potential for Altimmune’s pemvidutide, a GLP-1/Glucagon dual receptor agonist, in development for metabolic-dysfunction associated steatohepatitis (MASH), to help people with overweight and obesity lose weight.

The trial showed the drug significantly reduced body weight and serum lipids over 48 weeks of treatment. Subjects at the highest pemvidutide dose had lost an average of 15.6% of their total body weight.

Other potential benefits included significant decreases in the amount of lipids (such as cholesterol and triglycerides) present in the blood and the liver, which may help reduce the risk of cardiovascular disease.

Also this week, US scientists have released new data supporting initial findings that GLP-1 RA semaglutide (Wegovy/Ozempic) lowers cardiovascular risk regardless of blood sugar.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free